25Apr 2023
HER2 Mutations in NSCLC: How Genomics is Transforming Immunotherapy

HER2 Mutations in NSCLC: How Genomics is Transforming Immunotherapy

The study aims to assess the efficacy of immunotherapy in advanced HER2-mutated non-small cell lung cancer (NSCLC) and to compare the clinical and molecular features of patients with exon 20 insertion (ex20ins) and non-ex20ins. The study analyzed data from three cohorts and found that patients with non-ex20ins had potentially superior progression-free survival and overall survival under ICI-based therapy compared to ex20ins patients. The study suggests that ICI-based therapy may be an option for advanced HER2-mutated NSCLC, particularly in non-ex20ins patients. Further investigation is needed in clinical practice.

  • #oncology

Like

Save

Share